Loosening regulations on stem cell therapies could hurt and help patients

scientific american stemcells

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

On both coasts, campaigns are building to get desperate patients faster access to stem cell treatments — in some cases, before they are proven to work. And that is making some scientists nervous.

In Washington, a US senator recently introduced a bill that would allow the FDA to grant conditional approval to stem cell treatments without data from the big Phase 3 trials usually required before a drug hits the market. The bill has drawn the support of some stem cell companies, patient groups, and researchers, but a number of industry groups, scientists, and patient advocates have come out strongly in opposition.

Proponents say an accelerated regulatory process will help patients, but a chorus of critics warn that faster approvals could undermine the FDA’s authority to ensure that only rigorously tested therapies make it to market.


“There’s this misperception about why these trial requirements exist,” said Dr. Aaron Kesselheim, an expert on regulatory issues. “Clinicians need data to guide their decision-making, and patients want treatments that work.”

Read full, original post: Drive to get more patients experimental stem cell treatments stirs concerns

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend